you still need to pay 1.10 if you want to accept the right
unless you sell the right at market which is 0.375

http://hovidonlinestore.com/

dreaming

5.26 still in down mode.

still like a snail.

2.00 to 8.00. huat...

8.00 is coming

the share price down due to thailand issue.

need to wait after the football

good. than your share will be more. than wait until 1.20 than buy again

salesman keep on changing. that;s what i heard

for pharma one year down the road shall be higher price than current. at least 20 - 25%

Maintain ADD but lift our price target to RM5.45/share
Overall, we remain positive on Bonia. While we maiantain our FY14-16 EPS
forecast, we have however raise our price target from RM4.00 to RM5.45 (ex-all
RM1.36), as we: 1) roll over our valution horizon to CY15 EPS; and 2) raise our
target multiple from 13x to 15x. We peg the stock at a higher target multiple in
view of the corporate exercise which would definitely boost the stock’s liquidity.
We reckon that Bonia’s low liquidity has been an impediment for investors’
seeking to invest in the stock (average 6 month volume, 120,000 shares). With
an upside potential of 11%, we maintain our ADD recommendation on Bonia.
Key risk to our view is a sharp slowdown in regional consumer spending.

Maintain ADD but lift our price target to RM5.45/share
Overall, we remain positive on Bonia. While we maiantain our FY14-16 EPS
forecast, we have however raise our price target from RM4.00 to RM5.45 (ex-all
RM1.36), as we: 1) roll over our valution horizon to CY15 EPS; and 2) raise our
target multiple from 13x to 15x. We peg the stock at a higher target multiple in
view of the corporate exercise which would definitely boost the stock’s liquidity.
We reckon that Bonia’s low liquidity has been an impediment for investors’
seeking to invest in the stock (average 6 month volume, 120,000 shares). With
an upside potential of 11%, we maintain our ADD recommendation on Bonia.
Key risk to our view is a sharp slowdown in regional consumer spending.

5.03

5.15

Wait for announcement

Edited CIMB Research
We begin coverage of the stock with an Add rating and target price of
RM6.50, based on 19.2x CY15 P/E, a 20% premium over its 3-year average
forward P/E in view of its strong EPS CAGR of 28.1% for FY13-16. We like
its strong market positioning and manufacturing growth potential.
Stronger earnings and higher dividends are potential catalysts, in
our view.

Under-researched stock with strong earnings growth Pharmaniaga is an under-researched stock, in our view, as it is covered by only one broker currently, according to Bloomberg. However, we think that
Pharmaniaga warrants a closer look by investors.
The group is the largest pharmaceutical stock in Malaysia by market cap. It is well positioned to tap the rising healthcare spending in Malaysia via its
Concession Agreement with MOH. The group’s manufacturing division could
also benefit from the patent cliff, which allows it to launch more products in the next few years. We expect the manufacturing division to be the main thrust of earnings growth as in-house products have much higher profit margins vis-à-vis distributing third-party products.

are you sure. proof

drop today

normal lah up and down. when the selling done than upward again

see how the share price go.

normal lah up and down

actually after gst bonia profit margin may increase like 4%

normal lah. up and down.

will only sell when is 8.00

look like up 5.10

still have many to sell
so that's why down a lot

how yu value 40.00

Bonia - will up 50% o rmore

dksh not moving

Am research start calling.

just want tos ell and get out. world cup ...

4.23. down

3.76

will down because the share place is 0.42.

peak area - high irrigation cost, fertilizer cost, a lot of ncr area which the deman from local never end but still better than indonesia.

market not that good. so becareful.

3.60. buy or sell while can

still a penny share anyway.

let it be.

GHL SYSTEM (TP: RM1.00 or 15x FY14 EPS of 6.7 sen/share).

Our favourite company in the B2C segment of the
Payments Sector is GHL Systems for its dominate
market share, regional foot print and strong
management team.

The trend in GHL Systems Berhad fair value exchange rate
against its closest rated-competitor, HeiTech Padu Berhad, has been appreciating over the past 2 weeks. When compared to its closest competitor, HeiTech Padu Berhad, GHL Systems Berhad shows less overvaluation and is more likely to outperform the market.

HeiTech Padu Berhad's registered activity is in the IT Services & Consulting industry. The company
is a mid-cap stock currently trading at a multiple of 27.05 times earnings.

HeiTech Padu Berhad is a low quality company with a positive outlook.
HeiTech Padu Berhad has weak business growth and is run by passable
management. The trend in HeiTech Padu Berhad fair value exchange rate
against its closest rated-competitor, Theta Edge Berhad, has been
appreciating over the past 2 weeks. When compared to its closest peer,
GHL Systems Berhad, HeiTech Padu Berhad shows greater overvaluation
and is equally likely to underperform the market.

average buyback share is 2.39 as per annual report 2013.

take some profit. look like malaysia this year is not good for equity. rather look at other country

dksh, gtronic and so on all 100% return

must be public invetment bank want to sell the share. there is no research for it.